1 Katanoda K, Hori M, Matsuda T, Shibata A, Nishino Y, Hattori M, Soda M, Ioka A, Sobue T and Nishimoto H: An updated report on the trends in cancer incidence and mortality in Japan, 1958-2013. Jpn J Clin Oncol 45(4): 390-401, 2015. PMID:25637502. DOI: 10.1093/jjco/hyv002
2 Bray F, Ferlay J, Laversanne M, Brewster DH, Gombe Mbalawa C, Kohler B, Piñeros M, Steliarova-Foucher E, Swaminathan R, Antoni S, Soerjomataram I and Forman D: Cancer Incidence in Five Continents: Inclusion criteria, highlights from Volume X and the global status of cancer registration. Int J Cancer 137(9): 2060-2071, 2015. PMID: 26135522. DOI: 10.1002/ijc.29670
3 Harbeck N and Gnant M: Breast cancer. Lancet 389(10074): 1134-1150, 2017. PMID: 27865536. DOI: 10.1016/S0140-6736(16)31891-8
4 Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19(1): 27-39, 2018. PMID: 29242041. DOI: 10.1016/S1470-2045(17)30777-5
5 Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, Boileau JF, Brezden-Masley C, Chia S, Dent S, Gelmon K, Paterson A, Rayson D and Berry DA: Association of pathologic complete response to neoadjuvant therapy in HER2- positive breast cancer with long-term outcomes: A meta-analysis. JAMA Oncol 2(6): 751-760, 2016. PMID: 26914222. DOI: 10.1001/jamaoncol.2015.6113
6 Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blohmer J, Mamounas EP, Bergh J, Semiglazov V, Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W and von Minckwitz G: Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938): 164-172, 2014. PMID: 24529560. DOI: 10.1016/S0140-6736(13)62422-8
7 Bedard PL, Di Leo A and Piccart-Gebhart MJ: Taxanes: optimizing adjuvant chemotherapy for early-stage breast cancer. Nat Rev Clin Oncol 7(1): 22-36, 2010. PMID: 19997076. DOI: 10.1038/nrclinonc.2009.186
8 Gradishar WJ: Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother 7(8): 1041-1053, 2006. PMID: 16722814. DOI: 10.1517/14656566.7.8.1041
9 Gradishar WJ, Krasnojon D, Cheporov S, Makhson AN, Manikhas GM, Clawson A and Bhar P: Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27(22): 3611-3619, 2009. PMID: 19470941. DOI: 10.1200/JCO.2008.18.5397
10 Lee H, Park S, Kang JE, Lee HM, Kim SA and Rhie SJ: Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis. Sci Rep 10(1): 530, 2020. PMID: 31953463. DOI: 10.1038/s41598-019-57380-0
11 Chirgwin J and Chua SL: Management of breast cancer with nanoparticle albumin-bound (nab)-paclitaxel combination regimens: a clinical review. Breast 20(5): 394-406, 2011. PMID: 21839635. DOI: 10.1016/j.breast.2011.06.004
12 Megerdichian C, Olimpiadi Y and Hurvitz SA: nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. Cancer Treat Rev 40(5): 614-625, 2014. PMID: 24560997. DOI: 10.1016/j.ctrv.2014.02.001
13 Untch M, Jackisch C, Schneeweiss A, Conrad B, Aktas B, Denkert C, Eidtmann H, Wiebringhaus H, Kümmel S, Hilfrich J, Warm M, Paepke S, Just M, Hanusch C, Hackmann J, Blohmer JU, Clemens M, Darb-Esfahani S, Schmitt WD, Dan Costa S, Gerber B, Engels K, Nekljudova V, Loibl S, von Minckwitz G, German Breast Group (GBG) and Arbeitsgemeinschaft Gynäkologische Onkologie—Breast (AGO-B) Investigators: Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3): 345-356, 2016. PMID: 26869049. DOI: 10.1016/S1470-2045(15)00542-2
14 Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, Wiebringhaus H, Kümmel S, Warm M, Fasching PA, Just M, Hanusch C, Hackmann J, Blohmer JU, Rhiem K, Schmitt WD, Furlanetto J, Gerber B, Huober J, Nekljudova V, von Minckwitz G and Loibl S: NAB-paclitaxel improves disease-free survival in early breast cancer: GBG 69- GeparSepto. J Clin Oncol 37(25): 2226-2234, 2019. PMID: 31082269. DOI: 10.1200/JCO.18.01842
15 Nakazawa Y, Nakazawa S, Kurozumi S, Ogino M, Koibuchi Y, Odawara H, Oyama T, Horiguchi J, Fujii T and Shirabe K: The pathological complete response and secreted protein acidic and rich in cysteine expression in patients with breast cancer receiving neoadjuvant nab-paclitaxel chemotherapy. Oncol Lett 19(4): 2705- 2712, 2020. PMID: 32218821. DOI: 10.3892/ol.2020.11354
16 Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, Pippen JE, Bordelon JH, Kirby RL, Sandbach J, Hyman WJ, Richards DA, Mennel RG, Boehm KA, Meyer WG, Asmar L, Mackey D, Riedel S, Muss H and Savin MA: Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US oncology research trial 9735. J Clin Oncol 27(8): 1177-1183, 2009. PMID: 19204201. DOI: 10.1200/JCO.2008.18.4028
17 Yanai K, Fujii T, Horiguchi J, Nakazawa Y, Kurozumi S, Obayashi S, Yajima R and Shirabe K: Phase II study of sequential S-1 and cyclophosphamide therapy in patients with metastatic breast cancer. BMC Cancer 20(1): 1068, 2020. PMID: 33158432. DOI: 10.1186/s12885-020-07550-5
18 Yardley D, Burris H 3rd, Peacock N, Raefsky E, Melnik M, Inhorn R, Shipley D and Hainsworth J: A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophospha- mide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer. Breast Cancer Res Treat 123(2): 471- 475, 2010. PMID: 20658263. DOI: 10.1007/s10549-010-1047-0
19 Robidoux A, Buzdar AU, Quinaux E, Jacobs S, Rastogi P, Fourchotte V, Younan RJ, Pajon ER, Shalaby IA, Desai AM, Fehrenbacher L, Geyer CE Jr, Mamounas EP and Wolmark N: A phase II neoadjuvant trial of sequential nanoparticle albumin- bound paclitaxel followed by 5-fluorouracil/epirubicin/ cyclophosphamide in locally advanced breast cancer. Clin Breast Cancer 10(1): 81-86, 2010. PMID: 20133263. DOI: 10.3816/ CBC.2010.n.011
20 Kaklmani VG, Siziopikou K, Scholtens D, Lacouture M, Gordon J, Uthe R, Meservey C, Hansen N, Khan SA, Jeruss JS, Bethke K, Cianfrocca M, Rosen S, Roenn JV, Wayne J, Parimi V, Jovanovic B and Gradishar W: Piot neoadjuvant trial in HER2 positive breast cancer with combination of nab-paclitaxel and lapatinib. Breast Cancer Res Treat 132: 833-842, 2012. PMID: 21359953. DOI: 10.1007/s10549-011-1411-8
21 Tokunaga S, Takashima T, Kashiwagi S, Noda S, Kawajiri H, Tokumoto M, Nishimura S, Nishimori T, Ikeda K, Ogawa Y, Mizuyama Y, Sunami T, Tezuka K, Yamagata S, Ishikawa T, Kudoh S, Takada M, Hirakawa K and Ohira M: Neoadjuvant chemotherapy with nab-paclitaxel plus trastuzumab followed by 5-fluorouracil/epirubicin/cyclophosphamide for HER2-positive operable breast cancer: A multicenter phase II trial. Anticancer Res 39(4): 2053-2059, 2019. PMID: 30952749. DOI: 10.21873/anticanres.13316
22 Gianni L, Mansutti M, Anton A, Calvo L, Bisagni G, Bermejo B, Semiglazov V, Thill M, Chacon JI, Chan A, Morales S, Alvarez I, Plazaola A, Zambetti M, Redfern AD, Dittrich C, Dent RA, Magazzù D, De Fato R, Valagussa P and Tusquets I: Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/HER2-negative breast cancer-The evaluating treatment with neoadjuvant abraxane (ETNA) trial: A randomized phase 3 clinical trial. JAMA Oncol 4(3): 302-308, 2018. PMID: 29327055. DOI: 10.1001/jamaoncol.2017.4612
23 von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, Suter T, Arahmani A, Rouchet N, Clark E, Knott A, Lang I, Levy C, Yardley DA, Bines J, Gelber RD, Piccart M, Baselga J and APHINITY Steering Committee and Investigators: Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377(2): 122-131, 2017. PMID: 28581356. DOI: 10.1056/NEJMoa1703643